Ashwagandha root extract potency decline drivers in bulk storage

The study also reported shifts of more than 20% in HPLC fingerprint peaks and a statistically significant decline in immunomodulatory activity during the third month of accelerated storage (p < 0.01). For formulators, the practical point is straightforward: an assay describes a sample at a particular time. It does not predict how a different extract will perform in another package or warehouse.

The evidence considered here includes that peer-reviewed stability study and two supplier technical documents: a KSM-66 dossier from Cambridge Commodities dated May 31, 2018, and a Pioneer Biotech certificate of analysis dated March 17, 2019. They offer useful examples of how storage and shelf life are described for particular materials. They do not establish a universal degradation rate or a common storage standard for all bulk ashwagandha extracts.

Chemical profile of withanolide degradation in bulk storage

The 2009 study followed withanolide markers in a dried-root aqueous extract through real-time and accelerated storage. It reported marker loss in both study arms. The accelerated arm also showed a decline in immunomodulatory activity during its third month. These are findings about the extract and conditions examined; they should not be read as a forecast for every commercial root extract.

HPLC fingerprint changes add context, but they have limits. A shift in fingerprint peaks signals that the measured chromatographic profile changed. By itself, it does not identify which compounds changed, what reactions occurred, or how much of any individual constituent was lost. Nor is a fingerprint shift above 20% equivalent to a 20% drop in withanolide content. The measurements describe different things: one captures a broader profile, while the other concerns specified markers.

That distinction matters when interpreting supplier assays. A certificate of analysis can establish the result for the tested sample at the time of analysis, using the stated method and specification. It cannot establish the future potency of material held in bulk. A later test of the stored lot is needed to answer that question.

Supplier documentation also refers to stability work on the NMITLI-118RT+ standardized extract and recommends protecting that material from heat, moisture, aerial oxidation, and acidic or alkaline pH. This is useful as an example of extract-specific guidance. It should not be transferred without qualification to every ashwagandha powder or extract, whose composition, processing, and packaging may differ. The recommendation mentions oxidation as a storage concern for that particular extract; it is separate from the conditions reported for the 2009 study.

What the available evidence supports is narrower than a general shelf-life rule: marker loss was observed over the study period in one dried-root aqueous extract, including under real-time conditions. The published result does not establish a monthly rate, a universal timeline, or a potency trajectory for commercial bulk material as a category. For procurement and formulation teams, storage history and a current assay are more informative than an assumed rate of decline.

The phrase “potency decline” can also conceal several different questions. A buyer may mean a change in a specified withanolide marker, a shift in a broader chromatographic fingerprint, or a loss of a biological response. Those outcomes may be related, but the cited evidence does not make them interchangeable. A supplier’s marker specification cannot stand in for a bioactivity result, and a fingerprint comparison cannot answer how much of a single marker remains unless the relevant assay is performed.

That is why a useful stability record names the measurement rather than simply noting that an ingredient has “degraded.” It should identify the method, the analyte or endpoint, and the sample tested. When comparing results over time, teams also need to know whether the same analytical approach and comparable sample handling were used. Without that context, a changed result may be difficult to interpret, even when the number itself appears precise.

Moisture sensitivity and physical changes in dried-root extracts

The cited study reports moisture sensitivity exceeding 10%. That finding should be kept in its original form. It does not define a safe moisture ceiling for all extracts, nor does it give a universal threshold at which potency loss begins. A dried-root aqueous extract may respond differently from a material made with another extraction process or composition.

The Cambridge Commodities KSM-66 dossier classifies its material as hygroscopic. It specifies closed containers with desiccant, dry storage, and a temperature range of 15–30°C, with protection from moisture and direct sunlight. These are the supplier’s stated conditions for that product. They provide a practical reference when reviewing a lot from that supplier, not a substitute for the storage instructions attached to another ingredient.

The study also reports clump formation. Clumping is worth recording during inspection because it is a physical change in the material. But the cited evidence does not show that clumping proves a packaging failure, identifies the humidity conditions in the warehouse, or predicts a particular degree of withanolide loss. It is not a standalone potency test. The same caution applies to color: a visible change may prompt investigation, but the reviewed sources do not validate color as a quantitative proxy for assay.

For bulk handling, the useful distinction is between an observation and its interpretation. A receiving team can note whether powder is free-flowing or clumped, whether the seal is intact, and whether the container appears compromised. Those observations help reconstruct handling history. To determine moisture content or marker potency, the relevant test is needed; appearance cannot supply the missing measurement.

A lot-level record makes that distinction operational. At receipt, retain the supplier’s assay and storage instructions alongside the lot identity and the condition of the packaging. If moisture is measured, record the method and result rather than treating one study’s sensitivity finding as a pass/fail limit for every product. If the material later changes physically, compare the observation with the original record and investigate before drawing conclusions about chemical potency.

A visible change can be a reason to investigate. It is not a potency result.

Moisture control is also a packaging question, not just a warehouse question. A closed container can limit exposure during storage, while a desiccant may be part of a particular supplier’s instructions. But the presence of a desiccant does not, by itself, prove that a container remained properly sealed or that the material stayed within a moisture specification. The receiving record, subsequent handling, and any relevant test results complete the picture.

When a container is opened for sampling or production, the material’s handling history continues. Repeated opening can expose it to the conditions around it, so teams should follow the product’s own handling instructions and record meaningful departures. That does not establish that a particular opening caused potency loss. It does help explain why the condition of a lot cannot be inferred from its original certificate alone.

Impact of accelerated environmental conditions on bioactivity

Accelerated storage is useful for examining how a material responds under the conditions used in a study. It is not a direct calendar conversion that tells a buyer exactly what will happen to a commercial lot after a set number of months in a warehouse.

In the 2009 study, immunomodulatory activity declined during the third month of accelerated storage, and the decline was reported as statistically significant. The study’s reported result does not isolate the contribution of individual environmental factors. It therefore cannot establish that heat, moisture, or another condition alone caused a specific share of the observed decline.

This limits how far the result can be carried into a storage model. Heat, moisture, oxygen exposure, pH, and light may all be relevant considerations in supplier instructions or stability planning, but the cited study does not quantify an independent degradation rate for each. A proposed sequence in which one factor triggers a specific molecular reaction and another amplifies it would go beyond the reported evidence.

For a formulator, the practical response is to retain the conditions actually specified for the ingredient and document any departure from them. If a product dossier calls for a closed container, a dry place, or protection from light, those instructions belong in the handling record. If a material has been exposed to conditions outside its stated storage guidance, record the exposure and assess the lot with appropriate testing. The exposure alone does not reveal the remaining assay.

The distinction between chemical markers and biological activity matters here as well. A marker assay and a bioactivity result answer different questions. In the study, the reported activity decline occurred under its accelerated conditions; it does not establish that a given change in a marker assay will produce the same change in activity in another extract. Where a formulation depends on a defined biological endpoint, testing that endpoint may be necessary rather than inferring it from a chromatographic result.

Accelerated findings can guide questions for a stability program: which endpoints to follow, which storage instructions to document, and whether a particular product needs additional testing. They cannot fill gaps in the data. A result from one extract under one study design is a reason to take storage seriously, not a basis for assigning the same shelf life or degradation curve to every bulk ingredient.

Supplier packaging specifications and shelf-life variations

Two supplier documents show why storage and shelf-life statements need to be read product by product. The Cambridge Commodities dossier and Pioneer Biotech certificate differ in the specificity of their instructions and in the stated shelf-life period. Neither document establishes a market-wide rule.

The shelf-life periods are statements for the products described in those documents. They are not evidence that every ashwagandha extract remains within specification for the same period, nor do they prove that the stated period is an upper bound. The wording and conditions matter: Pioneer Biotech’s certificate ties its two-year period to proper storage, while the Cambridge Commodities dossier gives a minimum shelf life of 36 months. Those statements should be preserved as written in the relevant product documentation rather than generalized into a single industry rule.

The Pioneer document concerns one batch, manufactured March 15, 2019, and reports an assay of 2.56% against a specification of at least 2.5%. That result documents the tested batch at the time of analysis. It does not establish a supplier-wide potency floor or show what the batch would assay after storage. A new measurement is required to establish its condition at a later point.

For buyers working across multiple sources, supplier documents are a starting point for a lot-specific storage plan. Compare the stated container, temperature, moisture, and light guidance with the conditions available in the warehouse. Keep the documentation tied to the product and lot it describes. Where instructions differ, do not blend them into a generic rule without confirmation from the supplier.

Shelf life and potency are related, but they answer different practical questions. A shelf-life statement applies under its specified conditions and within the supplier’s framework. A later assay answers whether a particular retained lot meets the relevant specification at the time it is tested. Neither should be used as a substitute for the other: a date on a document does not measure the current lot, and a single assay does not rewrite the storage conditions under which shelf life was stated.

Making storage evidence useful in purchasing and formulation

The available evidence is enough to justify disciplined storage records, but not enough to support a universal monthly deduction from an assay. There is no degradation rate in the cited material that would allow a buyer to subtract a fixed amount of withanolide for every month in storage. The study’s observations also do not establish that all packaged bulk extracts lose potency on the same timeline.

A workable approach is to separate what the documents say from what the lot has demonstrated. The supplier specification defines the acceptance criteria for the material. The certificate records the tested sample. The storage history describes what happened after receipt. A follow-up assay can establish whether the stored lot still meets the relevant specification.

That approach is especially useful when a lot is held for an extended period, when storage conditions have varied, or when physical changes appear. In those cases, an in-house test can replace assumptions with evidence. The test should match the decision at hand: a marker assay for marker content, moisture testing for water content, or a relevant activity method where the formulation depends on a biological endpoint. Visual inspection helps document condition, but it cannot replace these measurements.

The central lesson is modest, and more useful for it. One study documents changes in a particular dried-root aqueous extract under particular storage conditions. Supplier documents give product-specific instructions and shelf-life statements. Neither source justifies a universal rate of potency loss. Bulk handling decisions should follow the relevant supplier specification, preserve the storage history, and use testing when the current condition of a lot matters.